Takeda has announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the ...
Investor's Business Daily on MSN
Zeta Global Holdings earns membership in 95-plus composite rating club
On Monday, Zeta Global Holdings ZETA got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. Please watch the ...
In addition, $14B Mather Group acquires a New Jersey-based firm, Prime Capital recruits an established RPA, and EY analysts ...
International study of microbiome data finds loss of beneficial bacteria and increase in bacteria from mouth lower in the gut ...
Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the Company entered into a global collaboration and exclusive ...
Investor's Business Daily on MSN
Dow Jones, S&P 500 fall from highs; Google leads AI stocks in buy zones
Dow Jones futures edged lower overnight, along with S&P 500 futures and Nasdaq futures.Wells FargoWFC, CitigroupC and Bank of ...
According to DataM Intelligence, the global Inflammatory Diseases Biologics Market was valued at USD 99.06 billion in 2024 and is projected ...
Dr Ray O’Connor takes a look at recent clinical articles on Diet and GI Issues, including the effects of caffeine, ...
Scientists at Sinai Health’s Lunenfeld-Tanenbaum Research Institute found antibodies to bacterial flagellin rose years before ...
Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics ...
Halozyme Therapeutics Inc. has entered into a global collaboration and exclusive license agreement with Takeda.
Insilico Medicine (3696.HK), a clinical-stage, generative AI-driven drug discovery company, today announced the completion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback